Where does Regulus Therapeutics Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Regulus Therapeutics Inc. ranks #7,465 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Regulus Therapeutics Inc. hold?

Regulus Therapeutics Inc. holds 44 US utility patents granted between 2015 and 2024, spanning 4 technology areas.

What is Regulus Therapeutics Inc.'s Innovation Score?

Regulus Therapeutics Inc. has an Innovation Score of 32.9 out of 100 (43rd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Regulus Therapeutics Inc.'s patent grant rate increasing or decreasing?

Regulus Therapeutics Inc.'s recent grant velocity is -87% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Regulus Therapeutics Inc.'s patents?

Regulus Therapeutics Inc.'s patents average 19.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Regulus Therapeutics Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Regulus Therapeutics Inc.

Q: What technology areas does Regulus Therapeutics Inc. focus on?

Regulus Therapeutics Inc.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 43 patents, ranking #240 of 4,144 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

USPTO PatentsView assignee record - 44 granted patents across 4 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Regulus ranks #7,465 of 49,997 tracked US assignees by granted-patent volume, with 44 patents across 4 technology areas.

#7,465
of 49,997 US assignees by volume: 43rd percentile
by Innovation Score (32.9/100): 19.3
avg claims per patent: -87%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7465 · US Corporation #7,465 · 44 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 44 grants
UPPER-Q #7,465/49,997
PHOTO-FINISH Portable Multimedia
CPC-NARROW C12N · 4 areas
INNOV-THIN 32.9/100
CLAIMS-RICH 19.3 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -87% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Portable Multimedia Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Regulus’s 32.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.1 pts (40%) Velocity 1.1 pts (3%) Breadth 7.1 pts (22%) Claim depth 11.6 pts (35%)

Qualcomm Incorporated · highest

85
Lin Engineering · near

33
Sarong Societa' Per… · near

33
Ceat · near

33
Regulus Therapeutics · this assignee

33
Ziel Home Furnishing… · near

33
3D Lighting… · lowest

7

What this shows Regulus's Innovation Score is 32.9/100 (43rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Regulus?

Each dot is one of Regulus’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Regulus’s own 19.3 claims/patent is ABOVE the 16.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Regulus vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Regulus's grants concentrate

Regulus Therapeutics Inc. is a focused PatentsView assignee: 4 CPC subclasses with 97.7% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2016 (10 grants) versus a trough of 1 in 2024. By volume, Regulus sits between Portable Multimedia Ltd. and SAFT.

Regulus's three-year grant acceleration

Regulus Therapeutics Inc. shows 1 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Portable Multimed…

44
Prismatic Sensors…

44
Protochips

44
Pulse Biosciences

44
Reliant Immune Di…

44
Roehm

44
Rondo Energy

44
SAFT

44
Regulus Therapeut… ◀

44

What this shows Regulus holds 44 patents at rank #7,465, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Regulus

By rank, the assignees closest to #7,465 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Regulus's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Regulus, neither rank-band nor same-CPC leaders (those blocks stay above). In C12N (Microorganisms OR Enzymes), Regulus ranks #240 of 4,144 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (33 here).

Ceat Limited 33 Ziel Home Furnishing Technology Co., Ltd. 33 Sarong Societa' Per Azioni 33 Lin Engineering, Inc. 33

Regulus's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 43rd percentile higher than 43% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Regulus Therapeutics Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	9	20.5%
2016	10	22.7%
2017	8	18.2%
2018	10	22.7%
2019	2	4.5%
2020	2	4.5%
2021	2	4.5%
2024	1	2.3%

Which technologies does Regulus Therapeutics Inc. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 43

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 40

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 27

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Regulus Therapeutics Inc.'s patent record in context - here's where to go next.

Regulus Therapeutics Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 97.7% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #7,465 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Regulus Therapeutics Inc. against Portable Multimedia Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.